Trial · NCT00424021
Results by group843
Each measurement the trial posted, group by group, in the words and numbers it posted.
61 to 80 of 843
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline (Week 24 of NCT00046319) in Exercise Capacity as Measured by the BDI (LOCF) (Week 156) | Combined Ambrisentan Treatment | 0.50 | Standard Deviation 1.888 | Units on a Scale | |
| Change From Baseline (Week 24 of NCT00046319) in Exercise Capacity as Measured by the BDI (LOCF) (Week 204) | Combined Ambrisentan Treatment | 0.46 | Standard Deviation 1.721 | Units on a Scale | |
| Baseline Measurement in Exercise Capacity as Measured by the World Health Organization (WHO) Functional Classification (Baseline [Week 24]) | Combined Ambrisentan Treatment | WHO Classification I | 8 | Participants | |
| Baseline Measurement in Exercise Capacity as Measured by the World Health Organization (WHO) Functional Classification (Baseline [Week 24]) | Combined Ambrisentan Treatment | WHO Classification II | 27 | Participants | |
| Baseline Measurement in Exercise Capacity as Measured by the World Health Organization (WHO) Functional Classification (Baseline [Week 24]) | Combined Ambrisentan Treatment | WHO Classification III | 19 | Participants | |
| Baseline Measurement in Exercise Capacity as Measured by the World Health Organization (WHO) Functional Classification (Baseline [Week 24]) | Combined Ambrisentan Treatment | WHO Classification IV | 0 | Participants | |
| Exercise Capacity as Measured by the WHO Functional Classification (LOCF) After 24 Weeks of Treatment in AMB-220-E | Combined Ambrisentan Treatment | WHO Classification I | 7 | Participants | |
| Exercise Capacity as Measured by the WHO Functional Classification (LOCF) After 24 Weeks of Treatment in AMB-220-E | Combined Ambrisentan Treatment | WHO Classification II | 29 | Participants | |
| Exercise Capacity as Measured by the WHO Functional Classification (LOCF) After 24 Weeks of Treatment in AMB-220-E | Combined Ambrisentan Treatment | WHO Classification III | 18 | Participants | |
| Exercise Capacity as Measured by the WHO Functional Classification (LOCF) After 24 Weeks of Treatment in AMB-220-E | Combined Ambrisentan Treatment | WHO Classification IV | 0 | Participants | |
| Exercise Capacity as Measured by the WHO Functional Classification (LOCF) After 84 Weeks of Treatment in AMB-220-E | Combined Ambrisentan Treatment | WHO Classification I | 5 | Participants | |
| Exercise Capacity as Measured by the WHO Functional Classification (LOCF) After 84 Weeks of Treatment in AMB-220-E | Combined Ambrisentan Treatment | WHO Classification II | 25 | Participants | |
| Exercise Capacity as Measured by the WHO Functional Classification (LOCF) After 84 Weeks of Treatment in AMB-220-E | Combined Ambrisentan Treatment | WHO Classification III | 21 | Participants | |
| Exercise Capacity as Measured by the WHO Functional Classification (LOCF) After 84 Weeks of Treatment in AMB-220-E | Combined Ambrisentan Treatment | WHO Classification IV | 3 | Participants | |
| Exercise Capacity as Measured by the WHO Functional Classification (LOCF) After 132 Weeks of Treatment in AMB-220-E | Combined Ambrisentan Treatment | WHO Classification I | 10 | Participants | |
| Exercise Capacity as Measured by the WHO Functional Classification (LOCF) After 132 Weeks of Treatment in AMB-220-E | Combined Ambrisentan Treatment | WHO Classification II | 18 | Participants | |
| Exercise Capacity as Measured by the WHO Functional Classification (LOCF) After 132 Weeks of Treatment in AMB-220-E | Combined Ambrisentan Treatment | WHO Classification III | 24 | Participants | |
| Exercise Capacity as Measured by the WHO Functional Classification (LOCF) After 132 Weeks of Treatment in AMB-220-E | Combined Ambrisentan Treatment | WHO Classification IV | 2 | Participants | |
| Exercise Capacity as Measured by the WHO Functional Classification (LOCF) After 180 Weeks of Treatment in AMB-220-E | Combined Ambrisentan Treatment | WHO Classification I | 10 | Participants | |
| Exercise Capacity as Measured by the WHO Functional Classification (LOCF) After 180 Weeks of Treatment in AMB-220-E | Combined Ambrisentan Treatment | WHO Classification II | 19 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00424021/results?page=4